



Leveraging Artificial Intelligence for Early Diagnosis of Colorectal Cancer: A Review

Dr. H S Nagalakshmi

Associate Professor and Head, Department of BCA, Government College for Women (Autonomous).
Mandya, Karnataka, India.

Abstract:

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Early detection significantly increases survival rates, yet conventional screening methods—particularly colonoscopy—faces limitations such as operator variability and lesion miss rates. Artificial Intelligence (AI), particularly deep-learning-based computer-aided detection (CADe) and diagnosis (CADx) systems, has emerged as a transformative tool capable of improving adenoma detection rate (ADR), identifying subtle or flat lesions, reducing miss rates, and standardizing diagnostic quality. This paper provides an extensive review of existing clinical evidence on AI-assisted colonoscopy, analyzes performance improvements, discusses technical approaches, identifies current challenges, and outlines the future direction of AI in CRC screening.

Keywords :

Artificial Intelligence, Colonoscopy, Colorectal Cancer, Early Detection, Computer-Aided Detection (CADe), Computer-Aided Diagnosis (CADx), Deep Learning, Medical Imaging, Polyp Detection, Adenoma Detection Rate.

I. Introduction

Colorectal cancer (CRC) is the *third most common cancer* and the *second leading cause of cancer deaths* globally according to the World Health Organization. Detecting precancerous lesions—adenomas and sessile serrated lesions—is essential to preventing malignant transformation. Colonoscopy is considered the gold standard for CRC screening; however, studies show that conventional colonoscopy misses **6–27% of adenomas**, especially flat or diminutive polyps.

AI systems, particularly those based on convolutional neural networks (CNNs), now assist clinicians by detecting abnormalities in real-time during colonoscopy. These systems review every video frame, highlight suspicious regions, and reduce human oversight errors.

This paper reviews evidence from randomized controlled trials, meta-analyses, and multi-center studies to assess AI's performance in early CRC detection.

Background and Motivation

Early CRC is often asymptomatic, making screening essential. However, several limitations affect conventional colonoscopy:

A. Operator-Dependent Variability

Endoscopist skill varies widely. Studies show ADR can differ by **up to 30%** among clinicians, directly affecting cancer prevention outcomes because every **1% increase in ADR reduces CRC risk by 3%–6%**.

B. Fatigue and Cognitive Load

Long procedures result in cognitive fatigue, increasing missed lesions especially toward the end of the day.

C. Flat and Sessile Lesions

Up to **9% of polyps** are flat or subtle in morphology, making them easy to miss even for experienced physicians. These challenges motivated the development of AI systems capable of real-time lesion recognition with improved consistency and accuracy.

A. Computer-Aided Detection (CAdE)

CAdE systems identify polyps during colonoscopy by analyzing video frames. Deep learning models, particularly CNNs, are trained on large annotated datasets to recognize patterns associated with polyps.

Functions include:

- Real-time visual alerts
- Bounding-box detection
- Frame-by-frame tissue analysis
- Sensitivity to texture and microstructure patterns

B. Computer-Aided Diagnosis (CAdx)

CAdx systems classify detected lesions as benign or malignant based on:

- Color patterns
- Vascular architecture
- Surface texture

These models support “optical biopsy,” potentially reducing unnecessary polypectomies.

C. Multimodal AI Integration

Future systems integrate:

- Narrow Band Imaging (NBI)
- Confocal laser endomicroscopy
- Stool DNA data
- Genomic biomarkers
- Electronic medical records

Such multimodal AI improves prediction accuracy and personalized screening strategies.

IV. Evidence from Clinical Studies

A. Improvement in Adenoma Detection Rate (ADR)

1. Meta-Analysis of 10 RCTs (n = 6629)

- AI-assisted colonoscopy increased ADR by **43% (RR = 1.43; p < 0.001)**.
- Increased detection of polyps, adenomas, and sessile serrated lesions.

2. Prospective Study (1,992 patients)

- ADR: **35.9% (AI) vs 26.4% (standard)** (p = 0.002)
- Polyp detection rate: **53.2% vs 46.2%**
- Adenomas per colonoscopy (APC): **0.69 vs 0.43**

3. Multi-Center Trial

- ADR increased from **38.5% to 47.9%** with AI (p = 0.03).

B. Reduction in Miss Rates

1. Tandem Colonoscopy Trials

- AI reduced adenoma miss rate by **54–56%**.

2. Detection of Small/Flat Lesions

- CAdE improved detection of:
 - Diminutive polyps (<5 mm)
 - Paris IIa flat lesions
 - Difficult serrated lesions

These lesions have the highest miss rates during conventional colonoscopy.

C. Enhanced Detection Efficiency with Minimal Time Cost

- Average increase in withdrawal time: **< 1 minute**.
- False positives are typically <1 per procedure, easily dismissed by clinicians.

D. Consistency Across Operators

- AI benefits both experienced and novice endoscopists.
- Reduces operator variability and maintains high-quality screening standards.

V. Discussion

AI offers compelling advantages in early CRC detection:

A. Clinical Impact

- Increased ADR is strongly associated with reduced risk of interval cancers.
- Improved detection of flat lesions reduces advanced pathology risk.

B. Workflow Integration

- AI systems integrate seamlessly with modern endoscopy units.
- Alerts are non-intrusive and enhance, not disrupt, clinical workflow.

C. Limitations

- False positives from mucosal folds or bubbles.
- Need for large, diverse datasets to reduce bias.
- Over-detection of diminutive polyps may increase unnecessary polypectomies.
- Long-term impact on CRC mortality not yet fully established.

D. Ethical and Regulatory Considerations

- Data privacy (HIPAA/GDPR compliance).
- FDA and CE approval requirements.
- Algorithm transparency and interpretability.

VI. Future Directions

A. Autonomous Polyp Classification

Combining CAdE + CAdx may create systems capable of autonomous decision support.

B. AI-Integrated Smart Endoscopes

Next-generation endoscopes will embed AI processors for real-time analysis without external hardware.

C. Personalized CRC Risk Models

AI will combine imaging + genomics + lifestyle factors to generate personalized CRC prevention strategies.

D. Home-Based Screening

AI-powered stool image analysis and DNA tests may offer accurate at-home detection.

VII. Conclusion

AI-assisted colonoscopy significantly improves adenoma detection rate, reduces miss rates, and standardizes screening quality. Clinical evidence consistently supports its role in enhancing early colorectal cancer detection. With continued improvements in algorithm accuracy, integration with imaging modalities, and broader clinical adoption, AI is poised to become an essential tool in global CRC prevention strategies.

References

- [1] J. Wang et al., "Effect of artificial intelligence-aided colonoscopy on adenoma detection: A meta-analysis of randomized controlled trials," *Gastrointestinal Endoscopy*, 2021.
- [2] G. Kim et al., "Artificial intelligence improves adenoma detection rate during colonoscopy," *Digestive Diseases and Sciences*, 2022.
- [3] S. Luo et al., "AI-assisted colonoscopy increases adenoma detection in routine clinical practice," *BMC Gastroenterology*, 2025.
- [4] M. Byrne et al., "Real-time polyp detection using deep learning in colonoscopy: Feasibility and clinical validation," *Gastroenterology*, 2020.
- [5] A. Repici et al., "Reduction of adenoma miss rate using computer-aided detection," *Endoscopy*, 2021.
- [6] J. Mori et al., "Optical biopsy of colorectal polyps using CAdx systems," *The Lancet Gastroenterology & Hepatology*, 2020.
- [7] S. Saito et al., "AI for serrated lesion detection: multicenter evaluation," *Clinical Gastroenterology and Hepatology*, 2022.
- [8] Y. Chen et al., "Deep learning in medical imaging for colorectal cancer screening: A systematic review," *IEEE Reviews in Biomedical Engineering*, 2023.
- [9] FDA, "Artificial Intelligence-enabled medical devices: Regulatory framework and approved systems," 2024.
- [10] WHO, "Global cancer statistics 2024: Colorectal cancer burden," World Health Organization.